Skip to content

13F-HR filed by Caligan Partners LP

Caligan Partners LP filed this 13F-HR for the quarter ended 2024-03-31, filed 2024-05-13, with 12 holding rows worth $378,314,062.

Accession
0001727492-24-000006
Filed
2024-05-13
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q1 2024

A holdings report, 12 entries on the cover page, a total value of $378,314,062 stated on the cover page (in dollars after the unit check, H1), rows summing to $378,314,062 with VALUE read as dollars as filed, 13F file number 028-23096. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
LIQUIDIA CORPORATION COM NEW53635D202Stock10,360,945$152,823,939dollars as filed
ALIMERA SCIENCES INC016259202COM16,835,154$65,657,101dollars as filed
ANIKA THERAPEUTICS INC035255108COM1,435,993$36,474,222dollars as filed
EVOLUS INC30052C107COM1,888,881$26,444,334dollars as filed
EXELIXIS INC COM30161Q104Stock1,100,730$26,120,323dollars as filed
VERONA PHARMA PLC925050106SPONSORED ADS1,296,447$20,859,832dollars as filed
ENANTA PHARMACEUTICALS INC29251M106COM858,070$14,981,902dollars as filed
AGIOS PHARMACEUTICALS INC00847X104COM484,711$14,172,950dollars as filed
Y-mAbs Therapeutics Inc984241109Common Stock587,276$9,549,108dollars as filed
OUTLOOK THERAPEUTICS INC69012T305COM500,000$5,970,000dollars as filed
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock758,502$3,853,190dollars as filed
NOVABRIDGE BIOSCIENCES44975P103CMN756,538$1,407,161dollars as filed

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001727492-24-000006this filing2024-05-13acceptance time not in the bulk data set